Ignite Creation Date:
2025-12-26 @ 1:19 PM
Ignite Modification Date:
2025-12-29 @ 6:06 PM
Study NCT ID:
NCT00440206
Status:
COMPLETED
Last Update Posted:
2007-02-27
First Post:
2007-02-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes
Sponsor:
Ottawa Hospital Research Institute
Organization:
Study Overview
Official Title:
Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Purpose is to identify whether immune markerscan predict success of salvage anti-retroviral therapy.
Detailed Description:
Over the last several years two markers of disease have been utilized to determine if antiretroviral therapy has been successful, one is a CD4 cell count (reflects the immunocompetence of an infected individual) and a HIV viral load (a blood test used to determine the amount of HIV in the infected individual). However in patients who fail their first line of therapythe likelihood of extended resuppressing viral replication with subsequent therapies may be as low as 25-50%. This information may take several months to determine the new therapies possible continuing success. It would be preferable to have additional markers that respond to therapies in the first several weeks to such therapies, therfore possibly offering patients alternate treatment earlier without potentiatinglong term side effects and possible further drug resistance.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: